Loading stock data…
KALV
$26.65-0.01 (-0.04%)
Market ClosedLast close May 1
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
KalVista Pharmaceuticals, Inc. in the Healthcare sector is trading at $26.65. The stock is currently near its 52-week high of $26.76, remaining 76.8% above its 200-day moving average. Technical signals show overbought RSI of 74 and bullish MACD crossover, explaining why KALV maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 74) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$26.65
Potential Upside
5%
Whystock Fair Value$27.98
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$977.33M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1194.76%
Volume
Today's trading volume
4.86M
Recent News
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout
Chiesi will assume ownership of Ekterly, an on-demand pill approved for hereditary angioedema.
IBT portfolio manager says KalVista deal signals Biotech 2.0 growth
International Biotechnology Trust (LSE:IBT) portfolio manager Ailsa Craig tells Proactive's Stephen Gunnion that M&A activity in biotech is running hot, with the proposed KalVista Pharmaceuticals acquisition by Chiesi Farmaceutici the latest in a string of deals — and 15% of IBT's portfolio has now been acquired year-to-date at an average premium of 50%. Craig explains the structural driver: big pharma is cash-rich but facing hundreds of billions in revenues lost to patent expiries, forcing them to acquire innovation. With biotech firms accounting for 70% of new drug approvals last year, the sector is firmly in the crosshairs. KalVista is held up as a textbook example of what Craig calls "Biotech 2.0" — clinically de-risked companies addressing real unmet needs. Its oral HAE treatment replaced injectable therapies, and Craig puts it simply: when patients feel an attack coming on, they now just take a tablet. IBT recycles proceeds from exits straight back into new opportunities, keeping the portfolio actively positioned to benefit from continued dealflow. For more insights like this, visit Proactive's YouTube channel, like this video, subscribe to the channel, and enable notifications so you never miss future updates. #Biotech #Pharma #MergersAndAcquisitions #BiotechInvesting #HealthcareStocks #KalVista #DrugDevelopment #InvestingInsights #BiotechNews #PharmaIndustry #StockMarket #HealthcareInnovation
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement
On April 29, 2026, a rare-disease deal reshapes biotech M&A expectations as investors weigh tender terms.
KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too
Shares of KalVista Pharmaceuticals catapulted Wednesday on a $1.9 billion takeover offer from Italy's Chiesi Group.
Sector Update: Health Care Stocks Fall Late Afternoon
Health care stocks declined late Wednesday afternoon, with the NYSE Health Care Index down 0.6% and